Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
Phio Pharmaceuticals Corp. reports developments as a clinical-stage siRNA biopharmaceutical company advancing its proprietary INTASYL® gene-silencing technology for immuno-oncology. Company updates center on PH-762, an INTASYL compound designed to silence the PD-1 gene and evaluated as an intratumoral therapy for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.
Recurring news themes include PH-762 clinical results, safety and pathology data, nonclinical toxicology work, cGMP clinical-supply manufacturing, regulatory-development steps, financial results, equity financing activity and investor presentations. Coverage also reflects the company's use of self-delivering RNAi technology intended to enhance immune-cell activity against tumor cells without specialized formulation or delivery systems.
Phio Pharmaceuticals (NASDAQ: PHIO) will present in a live Virtual Non-Deal Roadshow on April 29, 2026 at 12 PM EDT. CEO Robert Bitterman will overview the INTASYL siRNA platform, discuss PH-762 clinical progress, and host a live Q&A.
Phio reported 22 patients completed Phase 1b across five dose cohorts with no dose-limiting toxicities or serious adverse events; pathological response in cSCC was ~65% overall and 85% (6 of 7) in the highest-dose cohort.
Phio Pharmaceuticals (NASDAQ: PHIO) announced a virtual fireside chat on April 15, 2026 with Force Family Office featuring CEO Robert Bitterman and Dr. R. Todd Plott to discuss INTASYL siRNA program and PH-762, an intratumoral PD-1–silencing candidate for skin cancers.
Phio reported that 22 patients completed Phase 1b treatment across five dose cohorts with no dose-limiting toxicities or serious adverse events, ~65% pathological response in cSCC overall and 85% response (6 of 7) at the highest dose. FDA engagement on next-stage development is targeted for Q2 2026. Cash is projected to sustain operations into H1 2027.
Phio Pharmaceuticals (NASDAQ: PHIO) will present at the Centri Capital Conference on April 14, 2026 at Nasdaq Marketsite in New York City. CEO and Chairman Robert Bitterman will discuss recent clinical progress and the INTASYL PH-762 program in immuno-oncology.
The presentation is scheduled for 10:30 a.m. ET and will be available via virtual webcast; registration is through the conference registration link.
Phio Pharmaceuticals (NASDAQ: PHIO) entered a cGMP U.S. drug product manufacturing services agreement to supply its lead siRNA candidate PH-762 for clinical and potential commercial use. The move supports next-stage trials for intratumoral treatment of cutaneous carcinomas and secures domestic capacity for clinical supply.
Phio reported Phase 1b data: 22 patients treated with no dose-limiting toxicities, ~65% pathological response in cSCC across cohorts, and 85% response in the highest-dose cohort. FDA engagement is targeted for Q2 2026; cash runway is projected into H1 2027.
Phio Pharmaceuticals (NASDAQ: PHIO) will present Phase 1b clinical results for PH-762 at the American Academy of Dermatology Late-Breaking Research Session on March 28, 2026 at 3:00 PM MDT in Denver. The presentation reports 22 patients treated across five dose cohorts, no dose-limiting toxicities or serious adverse events, ~65% pathological response in cSCC overall and 85% response in the highest-dose cohort. FDA engagement for next-stage development is targeted for Q2 2026; cash runway is projected into H1 2027.
Phio Pharmaceuticals (NASDAQ: PHIO) will participate in a virtual fireside chat with Force Family Office on March 18, 2026 at 4 PM EDT to discuss its INTASYL gene‑silencing approach to immuno‑oncology.
Key clinical updates: lead candidate PH‑762 is in a Phase 1b intratumoral program (22 patients treated), with no dose‑limiting toxicities or serious adverse events, an overall pathological response in cSCC of ~65% and an 85% pathological response (6 of 7) in the highest dose cohort. The company targets FDA engagement in Q2 2026 and reports cash to sustain operations into H1 2027.
Phio Pharmaceuticals (NASDAQ: PHIO) will present live at the Life Sciences Investor Forum on March 12, 2026 at 11:00 AM ET. CEO Robert Bitterman will review the INTASYL siRNA platform, recent clinical progress for PH-762 and host a live Q&A. Replays and 1x1 meetings are available March 16–17. The company reported Phase 1b data showing ~65% pathological response in cSCC across doses, 85% (6 of 7) at the highest dose, no dose-limiting toxicities, planned FDA engagement in Q2 2026, and cash runway into H1 2027.
Phio Pharmaceuticals (NASDAQ: PHIO) reported 2025 year-end results and a business update. Key milestones include completion of the Phase 1b dose‑escalation for lead candidate PH‑762 with favorable safety and pathology signals, strengthening the balance sheet via financings and warrant exercises that generated $23.7 million in net proceeds, and cash of approximately $21.0 million at December 31, 2025.
The company advanced CMC and toxicology work, secured cGMP drug substance services, initiated a non‑clinical toxicology agreement, and targets an FDA meeting in Q2 2026 to seek guidance on next clinical steps.
Phio Pharmaceuticals (NASDAQ: PHIO) will present at Renmark's Virtual Non-Deal Roadshow on March 9, 2026 at 10 AM EDT to review its INTASYL siRNA platform and recent clinical progress for lead candidate PH-762.
In a Phase 1b trial, 22 patients completed treatment with no dose-limiting toxicities or serious adverse events; reported pathological response in cSCC was ~65% overall and 85% (6 of 7) in the highest-dose cohort. FDA engagement is targeted for Q2 2026. Cash is projected to sustain operations into H1 2027.
Phio Pharmaceuticals (NASDAQ: PHIO) announced leadership changes to support upcoming regulatory engagements and clinical milestones for PH-762 while continuing development of PH-894. Lisa Carson was promoted to Chief Financial Officer, Jennifer Phillips, Pharm.D., to Senior Vice President, Regulatory and Corporate Affairs, and Kimberly Man joined as Vice President of Program Development.
These appointments emphasize enhanced finance, regulatory strategy, and program coordination as the company prepares for the next stage of PH-762 clinical development.